The specter of generic rivalry has consistently loomed above copyright’s famous drug, PDE5 Inhibitor, raising questions about the outlook of related medicinal holdings. While first periods saw substantial profits, the intellectual property expiration has created the path for cheaper substitutes, possibly reducing revenue and presenting a real ris